Rosnilimab was safe and well tolerated in patients, who had similar adverse event rates as patients who received placebo. Data through week 12 showed no malignancies or major adverse cardiovascular events, no increase in serious infections and no anaphylaxis or systemic hypersensitivity reactions. Additionally, the study also showed a low incidence of injection site reactions in patient who received rosnilimab, similarly to those who received placebo.
Rosnilimab is currently under clinical investigation and has not been evaluated by a regulatory authority. It continues to be evaluated as a treatment for RA and is also in clinical trials for ulcerative colitis.
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
References
- A study of efficacy and safety of rosnilimab in subjects with moderate to severe rheumatoid arthritis (RENOIR) [NCT06041269]. AnaptysBio Inc. ClinicalTrials.gov. 2024 Nov 25.
- Anaptys announces rosnilimab achieved positive results in RA phase 2b trial and highest ever reported CDAI LDA response over 6 months [news release]. AnaptysBio Inc. 2025 Feb 12.
